APAC Antibodies Market

APAC Antibodies Market Size (2022 to 2027)

The size of the Antibodies Market in the Asia Pacific was valued at USD 14.23 Billion in 2022. This value is estimated to reach USD 22.78 Billion by the end of 2027, showcasing a growing potential of 9.87% CAGR during the forecast period.

The APAC region has the fastest growth rate of antibodies market in the world. The chronic disease burden of the region is increasing; thus, there is a rise in the research of monoclonal antibodies. The technological advancements and progressive R&D in the field of antibodies in Asia Pacific countries like India, China, Japan, and Australia are majorly expected to propel market growth. Antibodies are used in research to develop new diagnoses and treatments for rare diseases and to study different biomarkers of different conditions. There is significant adoption of therapeutic antibodies in this region, and the regulatory bodies in the area also have approved the treatment at a fast track without affecting safety. There are many antibody products in the clinical trials in the region, and the research has been going in this region to create a vaccine for COVID-19 by using the antibody resistance to coronavirus.

The cost of antibody treatment is high, and the process is complex, restraining the Asia Pacific market growth to some extent. In addition, there are some side effects of the antibody’s treatment like an allergic reaction, flu-like symptoms, vomiting, diarrhea, and low blood pressure, which are predicted to display a negative impact on the market to a limited extent. In addition, less awareness in undeveloped countries is further degrading the market growth. 

This research report on the APAC antibodies market has been segmented and sub-segmented into the following categories:

By Product Type:

• Monoclonal Antibodies
  • Murine
  • Chimeric
  • Humanized
  • Human
• Polyclonal Antibodies
  • Type I
  • Type II
  • Type III
  • Type IV
  • Type V
  • Type VI
  • Type VII
  • Type VIII
• Anti-body drug complexes
  • Immunogen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology

By Indication:

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Other)

By End User:

• Hospitals/Clinics
• Research institute
• Diagnostics laboratories

By Application:

• Medical
• Experimental
• Western blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, the Indian antibodies market is growing at the highest rate in this region. The National Institute of Immunology (NII) has generated monoclonal antibodies to detect typhoid fever and hepatitis B virus. NII is also developing monoclonal antibodies against rotavirus and virulent strains of E. coli. 

The Chinese antibodies market was leading the Asia Pacific market in 2020. China has many institutes that are researching antibodies. In addition, China is trying to develop a vaccine for COVID-19.

The Japanese government is promoting the production of biosimilar using antibodies. Japan has also developed antibodies for anti-glycosaminoglycan.

KEY MARKET PLAYERS:

Companies that play a promising role in the APAC antibodies market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly and company, A.G. Scientific, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.